The most advanced is a RASMULTI(ON) inhibitor, active against tumours harbouring KRAS-G12D and KRAS-G12V mutations, although their portfolio also includes KRAS-G12D- and KRAS-G13C-selective inhibitors [99]. The gene discussed is KRAS; the disease is neoplasm.